BRD-K10482608 can be considered a potential therapeutic agent for the treatment of HNSCC.<h4>Conclusion</h4>Our study highlighted the CR in risk stratification for HNSCC patients and ANXA1 in the pathogenesis of HNSCC, which can guide personalized and precision medicine for HNSCC patients. Here, ANXA1 is linked to head and neck squamous cell carcinoma.